home All News open_in_new Full Article

Novo Nordisk se desploma un 8% tras publicar datos de su nuevo fármaco contra obesidad

Las acciones de la farmacéutica danesa Novo Nordisk caen más del 8% en Bolsa después de que la compañía presentara los datos del segundo ensayo clínico de CagriSema, su nuevo medicamento contra la obesidad, cuyos resultados decepcionan a los inversores. Leer


today 3 w. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Economics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics


ID: 474583986
Add Watch Country

arrow_drop_down